Actively Recruiting

Phase 3
All Genders
NCT03808922

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

Led by Ansun Biopharma, Inc. · Updated on 2024-11-20

274

Participants Needed

67

Research Sites

327 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.

CONDITIONS

Official Title

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Requires supplemental oxygen of 2 liters per minute or more due to low blood oxygen at randomization
  • Immunocompromised by one or more of the following: prior hematopoietic stem cell transplant, solid organ transplant, chemotherapy for blood or solid tumors, congenital immunodeficiency (if under 18 years old), or pre-term birth (if 2 years old or younger)
  • Confirmed lower respiratory tract infection with a sialic acid dependent respiratory virus within 3 days before randomization
  • If female of childbearing potential, negative pregnancy test and agreement to use contraception
  • Non-vasectomized males must use effective birth control
  • Able to understand and comply with study procedures
  • Signed informed consent before any study procedures
  • For COVID-19 sub-study: 18 years or older, able to provide medical history, able to perform basic self-care before infection, confirmed lung infection involving at least 2 lobes by CT imaging, laboratory confirmation of SARS-CoV-2 infection, and meet main study criteria #1, 4, 5, 6, 7
Not Eligible

You will not qualify if you...

  • On hospice care or deemed unlikely to survive first 10 days of treatment
  • Elevated liver enzymes (ALT, AST, ALP) 3 times upper limit of normal or more and total bilirubin 2 times upper limit, unless stable for over 1 year due to known liver condition
  • Breastfeeding or planning to breastfeed through 30 days after last dose
  • Taking other investigational drugs for pulmonary infection
  • Psychiatric, cognitive, or substance use issues that affect safety or compliance
  • Known allergy to DAS181 or its components
  • Severe sepsis with organ failure outside lung or requiring blood pressure support
  • For COVID-19 sub-study: on invasive mechanical ventilation, Bi-PAP or CPAP at randomization; receiving other investigational or empiric treatments for SARS-CoV-2; known HIV positive without undetectable viral load; currently taking immunomodulating biologics; severe sepsis with organ failure or blood pressure support; and meeting main study exclusion criteria #2, 3, 5, 6

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 67 locations

1

City of Hope cancer Center

Duarte, California, United States, 91010

Actively Recruiting

2

UCLA

Los Angeles, California, United States, 90024

Active, Not Recruiting

3

University of California Davis Health System

Sacramento, California, United States, 95817

Actively Recruiting

4

University of California San Diego Medical Center

San Diego, California, United States, 92093

Withdrawn

5

Children's Hospital Colorado

Aurora, Colorado, United States, 80045

Withdrawn

6

Sylvester Comprehensive Cancer Center, University of Miami Health System

Miami, Florida, United States, 33136

Actively Recruiting

7

Houston Methodist Hospital

Tampa, Florida, United States, 33612

Withdrawn

8

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States, 60611

Actively Recruiting

9

University of Chicago

Chicago, Illinois, United States, 60637

Withdrawn

10

Loyola University Medical Center

Maywood, Illinois, United States, 60153

Withdrawn

11

University of Iowa Health Care

Iowa City, Iowa, United States, 52242

Actively Recruiting

12

University of Kansas Medical Center

Fairway, Kansas, United States, 66205

Actively Recruiting

13

Louisiana State University

Shreveport, Louisiana, United States, 71103

Completed

14

University of Maryland

Baltimore, Maryland, United States, 21201

Withdrawn

15

The Johns Hopkins Hospital

Baltimore, Maryland, United States, 21205

Withdrawn

16

Brigham and Women's Hospital

Boston, Massachusetts, United States, 02115

Actively Recruiting

17

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02215

Withdrawn

18

Universtiy of Michigan

Ann Arbor, Michigan, United States, 48109

Withdrawn

19

Mayo Clinic Rochester

Rochester, Minnesota, United States, 55905

Actively Recruiting

20

Washington University

St Louis, Missouri, United States, 63112

Withdrawn

21

University of Nebraska Medical Center

Omaha, Nebraska, United States, 68198

Withdrawn

22

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

Withdrawn

23

Weill Cornell Medical College

New York, New York, United States, 10065

Actively Recruiting

24

Duke University

Durham, North Carolina, United States, 27710

Actively Recruiting

25

Novant Health

Winston-Salem, North Carolina, United States, 27103

Withdrawn

26

The Lindner Center- The Christ Hospital

Cincinnati, Ohio, United States, 45219

Withdrawn

27

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States, 45267

Actively Recruiting

28

University of Cincinnati

Cincinnati, Ohio, United States, 45267

Withdrawn

29

The Cleveland Clinic Foundation

Cleveland, Ohio, United States, 44106

Withdrawn

30

St. Elizabeth Youngstown Hospital

Youngstown, Ohio, United States, 44501

Withdrawn

31

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, United States, 73104

Actively Recruiting

32

Oregon Health & Science University

Portland, Oregon, United States, 97239

Withdrawn

33

University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

Withdrawn

34

University of Pittsburgh Medical Center Health System

Pittsburgh, Pennsylvania, United States, 15213

Actively Recruiting

35

Kent Hospital

Warwick, Rhode Island, United States, 02886

Completed

36

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37232

Withdrawn

37

UT Southwestern Medical Center

Dallas, Texas, United States, 75390

Actively Recruiting

38

Cook Children's

Fort Worth, Texas, United States, 76104

Terminated

39

Texas Health

Fort Worth, Texas, United States, 76104

Completed

40

Therapeutic Concepts

Houston, Texas, United States, 77004

Completed

41

Baylor College of Medicine

Houston, Texas, United States, 77030

Actively Recruiting

42

Houston Methodist Hospital

Houston, Texas, United States, 77030

Withdrawn

43

MD Anderson

Houston, Texas, United States, 77030

Actively Recruiting

44

VCU Health System

Richmond, Virginia, United States, 23298

Actively Recruiting

45

Seattle Children's Hospital

Seattle, Washington, United States, 98105

Actively Recruiting

46

Fred Hutchinson Cancer Center

Seattle, Washington, United States, 98109

Actively Recruiting

47

Fred Hutchinson Cancer Research Center

Seattle, Washington, United States, 98109

Actively Recruiting

48

Medical College of Wisconsin

Milwaukee, Wisconsin, United States, 53226

Actively Recruiting

49

Froedtert Medical College Pulmonary Clinic

Milwaukee, Wisconsin, United States, 53266

Actively Recruiting

50

Westmead Hospital

Sydney, New South Wales, Australia, 2145

Terminated

51

The Wesley Hospital

Auchenflower, Queensland, Australia, 4066

Terminated

52

Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia, 3050

Terminated

53

Royal Melbourne Hospital

Melbourne, Victoria, Australia, 3050

Terminated

54

Shanghai Pulmonary Hospital

Yangpu, Shanghai Municipality, China, 200433

Terminated

55

West China Hospital

Chengdu, Sichuan, China, 610041

Terminated

56

Shulan (Hangzhou) Hospital co., LTD

Hangzhou, Zhejiang, China

Terminated

57

The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Terminated

58

Rigshospitalet

Copenhagen, Denmark, 2100

Terminated

59

Hôpital Henri Mondor

Créteil, Île-de-France Region, France, 94010

Terminated

60

Prince of Wales Hospital

Shatin, New Territories, Hong Kong

Terminated

61

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, South Korea, 13620

Terminated

62

Seoul National University Hospital

Seoul, Gyeonggi-do, South Korea, 03080

Terminated

63

Asan Medical Center

Seoul, Gyeonggi-do, South Korea, 05505

Terminated

64

Samsung Medical Center

Seoul, Gyeonggi-do, South Korea, 06351

Terminated

65

The Catholic University of Korea, Seoul St. Mary's Hospital

Seoul, Gyeonggi-do, South Korea, 06591

Terminated

66

National Taiwan University Hospital

Zhongzheng, Taipei City, Taiwan, 10002

Terminated

67

National Cheng Kung University Hospital

Tainan, Taiwan

Terminated

Loading map...

Research Team

L

Lisa Li

CONTACT

L

Lana Ordonez

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

6

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here